Search hospitals > Texas > Lubbock
Joe Arrington Cancer Research and Treatment Center
Claim this profileLubbock, Texas 79410
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lymphoma
144 reported clinical trials
3 medical researchers
Summary
Joe Arrington Cancer Research and Treatment Center is a medical facility located in Lubbock, Texas. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Non-Small Cell Lung Cancer, Lymphoma and other specialties. Joe Arrington Cancer Research and Treatment Center is involved with conducting 144 clinical trials across 90 conditions. There are 3 research doctors associated with this hospital, such as Isaac Tafur, Kiran K. Yalamanchili, and Ibrahim A. Shalaby.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
Stage III
2Lung Cancer
Global Leadermetastatic
locally advanced
Stage IV
Top PIs
Isaac TafurJoe Arrington Cancer Research and Treatment Center10 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Cancer
7 reported clinical trials
12 drugs studied
Kiran K. YalamanchiliCovenant Medical Center-Lakeside5 years of reported clinical research
Studies Lung Cancer
Studies Cancer
6 reported clinical trials
30 drugs studied
Ibrahim A. ShalabyCovenant Medical Center-Lakeside9 years of reported clinical research
Studies Breast Cancer
Studies Coronavirus
4 reported clinical trials
12 drugs studied
Clinical Trials running at Joe Arrington Cancer Research and Treatment Center
Breast Cancer
Multiple Sclerosis
Squamous Cell Carcinoma
Multiple Myeloma
Pancreatic Cancer
Sclerosis
Plasma Cell Neoplasms
Recurrence
Cancer
Colorectal Cancer
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Ovarian Suppression Therapy
for Breast Cancer
This trial tests TOL2506, a treatment that stops ovaries from working, in premenopausal women and men with hormone-sensitive breast cancer. It aims to reduce hormone levels to slow down or stop cancer growth. TOL2506 is a treatment that stops ovaries from working, similar to other ovarian suppression methods.
Recruiting2 awards Phase 39 criteria
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Joe Arrington Cancer Research and Treatment Center?
Joe Arrington Cancer Research and Treatment Center is a medical facility located in Lubbock, Texas. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Non-Small Cell Lung Cancer, Lymphoma and other specialties. Joe Arrington Cancer Research and Treatment Center is involved with conducting 144 clinical trials across 90 conditions. There are 3 research doctors associated with this hospital, such as Isaac Tafur, Kiran K. Yalamanchili, and Ibrahim A. Shalaby.